Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK
Beta0.98
Shares Outstanding14.6M
Average Volume (10 days)92.1K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.09)
Sales (TTM)$10.43
Book Value (MRQ)$19.50
Cash Flow (TTM)$0.58
Cash (MRQ)$6.01

Analyst Views

Current Mean RecommendationBuy
Strong Buy1
 
Buy0
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

John B. Henneman
Director
7,954
Acquire
Jun 8, 2022
Sheryl L. Conley
Director
7,954
Acquire
Jun 8, 2022
Susan L.N. Vogt
Director
7,954
Acquire
Jun 8, 2022
Stephen Richard
Director
7,954
Acquire
Jun 8, 2022
Glenn R. Larsen
Director
7,954
Acquire
Jun 8, 2022

Recent SEC Filings

Quarterly Financials
Nov 9, 2022
Company Events
Nov 8, 2022
Company Events
Nov 1, 2022
>= 5% Acquisition
Oct 7, 2022
Insider Buy/Sell
Aug 11, 2022
To Top